Wire · regulatory
FDA Approves Atezolizumab Plus Chemotherapy for Adjuvant Treatment of Stage III dMMR ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 October 2026 · Fusion42 review
The FDA has approved atezolizumab combined with fluoropyrimidine- and oxaliplatin-based chemotherapy as an adjuvant treatment for stage III mismatch repair deficient (dMMR) colon cancer in adults and pediatric patients 2 years and older, with both intravenous and subcutaneous administration options. The approval is based on the ATOMIC trial demonstrating a 50% reduction in the risk of disease recurrence or death versus chemotherapy alone.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 8 Oct 2026 and 10 Oct 2026.
◆ ◆ The Wire takeaway
You face a new FDA-approved treatment option integrating immunotherapy with chemo for stage III dMMR colon cancer, expanding your product development or clinical deployment strategies. The novel use of subcutaneous atezolizumab creates fresh pathways for patient-friendly drug delivery models you can exploit.
◆ Coverage
5 sources · first reported 8 Oct 2026 · latest 10 Oct 2026
◆ Related on Wire
◆ Topics